Literature DB >> 2724013

Improvement in survival after excision of primary tumor in stage III neuroblastoma.

G M Haase1, K Y Wong, A A deLorimier, H N Sather, G D Hammond.   

Abstract

Fifty-eight patients with stage III neuroblastoma (according to the Childrens Cancer Study Group) underwent 86 operative procedures. Initial diagnostic or therapeutic operations were followed by chemotherapy and radiation therapy, and second- or third-look procedures were performed on patients whose tumors showed evidence of clinical response. Complete resection was obtained during the initial procedure in 12 patients, during the second operation in 12 others, and at the time of the third procedure in two additional children. Twenty of these 26 patients have survived with no evidence of disease for a median duration of greater than 3 years since initiation of therapy. Only nine of the 32 patients in whom complete tumor excision could not be accomplished are still alive. The chemotherapy and radiation therapy employed in this protocol may have enhanced resectability in many patients. The site of the primary tumor does not seem to influence ease of resectability or outcome in this group. The "favorable" prognostic factors of patient age and histopathology of the tumor do not necessarily predict that the tumor will be resectable. While patients with complete resection at the time of the second operation had an outcome superior to those with incomplete resections, the influence of the inherent tumor biology or other selection factors on the eventual tumor resectability in these patients is not known. Extensive operative procedures were required to completely resect stage III tumors, and a moderate complication rate may be anticipated. However, this may be justifiable if complete tumor resection can be achieved and ultimate patient survival possibly enhanced.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2724013     DOI: 10.1016/s0022-3468(89)80248-9

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

1.  What is the result: chylous leakage following extensive radical surgery of neuroblastoma.

Authors:  Yin Liu; Ci Pan; Jing-Yan Tang; Jing Chen; Min Zhou; Qi-Dong Ye
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Prognostic importance of DNA flow cytometrical, histopathological and immunohistochemical parameters in neuroblastomas.

Authors:  N L Carlsen; K Ornvold; I J Christensen; H Laursen; J K Larsen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

3.  Intensive chemotherapy in children with stage IV neuroblastoma.

Authors:  P Kusumakumari; T V Ajithkumar; S Hariharan; R R Varma; V G Chellam; R Nair; M K Nair
Journal:  Indian J Pediatr       Date:  1999 Nov-Dec       Impact factor: 1.967

4.  Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma.

Authors:  Chee-Chee Koh; Jin-Cherng Sheu; Der-Cherng Liang; Shu-Huey Chen; Hsi-Che Liu
Journal:  Pediatr Surg Int       Date:  2005-01-13       Impact factor: 1.827

5.  Intraoperative radiotherapy in the treatment of neuroblastoma: report of a pilot study.

Authors:  D R Aitken; G A Hopkins; J O Archambeau; D C Moores; D A Weeks; A A Bedros; H G Andrews; J W Smith
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

6.  Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma.

Authors:  R S Chamberlain; R Quinones; P Dinndorf; N Movassaghi; M Goodstein; K Newman
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

7.  Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience.

Authors:  G M Haase; M C O'Leary; D O Stram; J N Lukens; R C Seeger; H Shimada; K K Matthay
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

8.  Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).

Authors:  H Rubie; J Michon; D Plantaz; M C Peyroulet; C Coze; D Frappaz; P Chastagner; M C Baranzelli; F Méchinaud; P Boutard; P Lutz; Y Perel; G Leverger; L de Lumley; F Millot; J L Stéphan; G Margueritte; O Hartmann
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

9.  Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy.

Authors:  H Rubie; C Coze; D Plantaz; C Munzer; A S Defachelles; C Bergeron; C Thomas; P Chastagner; D Valteau-Couanet; J Michon; V Mosseri; O Hartmann
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.